An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.

doi:10.1038/nbt0598-444

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.

Nature biotechnology - 1 May 1998

Chase M, Chung R Y, Chiocca E A

Abstract excerpt

Herpes simplex viruses type 1 (HSV-1) with an inactivated viral ribonucleotide reductase (Hsrr, ICP6) were designed to target tumor cells with upregulated mammalian ribonucleotide reductase (mRR), an enzyme whose expression is regulated by the p16/pRB tumor suppressor pathway. A recombinant HSV-1 was generated by knock-out of Hsrr and insertion of the rat CYP2B1 transgene responsible for the bioactivation of the...

Topics

Animals
Antineoplastic Agents, Alkylating
Cyclophosphamide
Cytochrome P-450 CYP2B1
DNA, Viral
Gene Expression Regulation, Enzymologic
Herpesvirus 1, Human
Humans
Ifosfamide
Mice
Mice, Nude
Mutation
Prodrugs
Rats
Recombinant Proteins
Ribonucleotide Reductases
Tumor Cells, Cultured
Up-Regulation

Source

Open in PubMed

Identifiers

PMID: 9592392
DOI: 10.1038/nbt0598-444

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics